Publications by authors named "Jing-Nan Xue"
Article Synopsis
- PD-1 inhibitors, alongside lenvatinib and transarterial chemoembolization (TACE), may offer improved outcomes for patients with unresectable hepatocellular carcinoma (uHCC) compared to standard lenvatinib and TACE treatment.
- A study of 65 patients found that those receiving the combination therapy had a significantly longer overall survival time of 26.8 months versus 14.0 months for the standard treatment group.
- The research utilized various assessment criteria to evaluate both efficacy and safety, highlighting the advantages of combining PD-1 inhibitors with other treatments for better patient prognosis.
High incidence combination of multiple primary malignant tumors of the digestive system.
World J Gastroenterol
November 2022
Article Synopsis
- * It aims to identify common combinations of metachronous (occurring at different times) and synchronous (occurring simultaneously) MPMTs by analyzing 1902 patients from a specific hospital.
- * The study found that a significant majority of cases (95.2%) were secondary cancers, with most being diagnosed as metachronous tumors, and highlighted the importance of understanding these common combinations to improve patient treatment.
Novel cellular therapies for hepatobiliary malignancies.
Hepatobiliary Pancreat Dis Int
October 2022
Background: The mortalities of hepatobiliary malignancies are high. With the failure of conventional chemotherapy and unsatisfactory outcome of molecular targeted drugs, immune-based therapy has become a new focus of research in hepatobiliary cancers treatment.
Data Sources: We performed a PubMed search with relevant articles published up to May 2022 and the following keywords: cellular immunotherapy, hepatobiliary cancer, antigen receptor T cell therapy, and receptor-engineered T cell.